Biodegradable and biocompatible nanoparticles for targeted drug delivery applications

Biodegradable and biocompatible nanoparticles are emerging as powerful drug delivery systems due to their ability to enhance therapeutic efficacy while minimizing side effects. They offer key advantages over conventional delivery methods, including improved bioavailability, targeted delivery, and reduced systemic toxicity. Various classes—such as polymeric, lipid-based, protein-based, and dendrimer nanoparticles—provide versatile platforms for customizing treatment strategies. Nanoparticle-mediated drug delivery operates through mechanisms such as passive and active targeting, controlled release, and efficient cellular uptake. Surface modifications, including PEGylation and ligand attachment, further improve specificity, stability, and pharmacokinetics. These systems have shown significant success in cancer therapy by overcoming multidrug resistance and enabling selective tumor targeting. They also hold promise in neurological diseases by facilitating transport across the blood–brain barrier and in infectious diseases by enhancing the delivery and efficacy of antiviral and antibacterial agents. Despite their potential, challenges remain in translating nanoparticles to clinical use. Issues include scalability, reproducibility, complex synthesis processes, and the need for thorough safety evaluation of nanoparticles and their degradation products. Regulatory agencies like the FDA and EMA are developing guidelines to support approval. Emerging trends such as smart, stimuli-responsive, and bioinspired nanoparticles, along with personalized nanomedicine, are expected to drive future therapeutic advancements.